Современные аспекты хронической обструктивной болезни легких. Проф. Ж.Д. Семидоцкая, доц. И.А. Чернякова, ас. Е.Н. Пионова, ас. Н.С. Трифонова. | Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini

Prof. Z.D. Semidotska, PHD I.A. Chernyakova, PHD O.M. Pionova, PHD N.S. Tryfonova. Kharkiv National Medical University. Department of Propedeutics of Internal Medicine №2 and nursing.

The current data of the diagnosis, treatment and rehabilitation of patients with chronic obstructive pulmonary disease are presented with article. Diagnosis and treatment algorithms based on pathogenetic and clinical aspects of chronic obstructive pulmonary disease are mentioned.

Results of diagnosis and treatment algorithms based pathogenetic and clinical aspects of chronic obstructive pulmonary disease.

Key Words: chronic obstructive pulmonary disease, diagnosis, treatment.

Semidotska ZD, Chernyakova IA, Pionova OM, Tryfonova NS. [Modern aspects of chronic obstructive pulmonary disease]. Shidnoevr. z. vnutr. simejnoi med. 2016;2:4-12. Ukrainian.

https://doi.org/10.15407/internalmed2016.02.001

Download.PDF

1. Antonelli-Incalzi R, Pedone C, Scarlata S, Battaglia S, Scichilone N, Forestiere F, Bellia V. Correlates of mortality in elderly COPD patients: focus on health-related quality of life. Respirology. 2009 Jan;14(1):98-104. DOI: 10.1111/j.1440-1843.2008.01441.x https://doi.org/10.1111/j.1440-1843.2008.01441.x

2. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J. 2003 Oct;22(4):672-88. PMID: 14582923

3. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. PLoS One. 2013 May 17;8(5):e63285. doi: 10.1371/journal.pone.0063285. https://doi.org/10.1371/journal.pone.0063285

4. Brashier BB, Kodgule R. Risk factors and pathophysiology of chronic obstructive pulmonary disease (COPD). J Assoc Physicians India. 2012 Feb;60 Suppl:17-21. PMID: 23155808.

5. Burge S. Wedzicha JA, Respir J. COPD exacerbations: definitions and classifications. The European respiratory journal. 2003 Jun;41:46s-53s. DOI: 10.1183/09031936.03.00078002. https://doi.org/10.1183/09031936.03.00078002

6. Burrows B, Niden AH, Barclay WR, Kasik JE. Chronic obstructive lung disease II. Relationships of clinical and physiological findings to the severity of aiways obstruction . The American review of respiratory disease. 1965 May;91:665-78.

7. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. The European respiratory journal. Eur Respir J. 2007 Jun;29(6):1224-38. PMID: 17540785. DOI: 10.1183/09031936.00109906. https://doi.org/10.1183/09031936.00109906

8. Decramer M, Celli В, Kestenat S. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009 Oct 3;374(9696):1171-8. PMID: 19716598. DOI: 10.1016/S0140-6736(09)61298-8. https://doi.org/10.1016/S0140-6736(09)61298-8

9. Definition and classification of chronic bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1965 Apr 10;1(7389):775-9. PMID: 4165081.

10. Divo M, Cote С, de Torres JP, Casanova C, Marin JM. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 2012 Jul 15;186(2):155-61. doi: 10.1164/rccm.201201-0034OC https://doi.org/10.1164/rccm.201201-0034OC

11. Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):770-7. PMID: 11549531. DOI: 10.1164/ajrccm.164.5.2012122 https://doi.org/10.1164/ajrccm.164.5.2012122

12. Echave-Sustaeta JM, Comeche Casanova L, Cosio BG. Comorbidity in chronic obstructive pulmonary disease. Related to disease severity? Int J Chron Obstruct Pulmon Dis. 2014 Nov 19;9:1307-14. doi: 10.2147/COPD.S71849. https://doi.org/10.2147/COPD.S71849

13. Georgopoulas D, Anthonisen NR. Symptoms and signs of COPD. In: Cherniack NS, ed. Chronicobstructive pulmonary disease. Toronto: WB Saunders Co. 1991. Р. 357—363.

14. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Global Initiativefor Chronic Obstructive Lung Disease (GOLD) 2016. Updated 2016. Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65. URL: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html.

15. Guyatt GH, Berman BL, Townsend М. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987 Oct; 42(10): 773–778. PMID: 3321537. PMCID: PMC460950.

16. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med. 1999 Sep;160(3):893-8. DOI: 10.1164/ajrccm.160.3.9901091 https://doi.org/10.1164/ajrccm.160.3.9901091

17. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004 Aug 21-27;364(9435):709-21. DOI: 10.1016/S0140-6736(04)16900-6 https://doi.org/10.1016/S0140-6736(04)16900-6

18. Hurst JR, Vestbo J, Anzueto A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883. https://doi.org/10.1056/NEJMoa0909883

19. Janson C. Pneumonia and pneumonia related in patients with COPD treated fixed combination og inhaled corticosteroid and ling acting beta2- agonist: observational matched cohort study (PATOS). BMJ. 2013 May 29;346:f3306. doi: 10.1136/bmj.f3306. https://doi.org/10.1136/bmj.f3306

20. Jenkins CR, Jones PW, Calverley PM. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomized, placebo-controlled TORCH study. Respir Res. 2009 Jun 30;10:59. doi: 10.1186/1465-9921-10-59. https://doi.org/10.1186/1465-9921-10-59

21. Jones PW. COPD assessment test – rationale, development, validation and performance. COPD. 2013 Apr;10(2):269-71. doi: 10.3109/15412555.2013.776920. https://doi.org/10.3109/15412555.2013.776920

22. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure for chronic airflow limitation – the St George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992 Jun;145(6):1321-7. DOI: 10.1164/ajrccm/145.6.1321 https://doi.org/10.1164/ajrccm/145.6.1321

23. Jones PW, Harding G, Berry P, Wiklund I. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009 Sep;34(3):648-54. doi: 10.1183/09031936.00102509. https://doi.org/10.1183/09031936.00102509

24. MacNee W, Rabinovich RA, Choudhury G. Ageing and the border between health and disease. Eur Respir J. 2014 Nov;44(5):1332-52. doi: 10.1183/09031936.00134014. https://doi.org/10.1183/09031936.00134014

25. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med. 2001 Feb;7(2):55-62. DOI: 10.1016/S1471-4914(01)01912-8 https://doi.org/10.1016/S1471-4914(01)01912-8

26. Mannino DM, Higuchi K, Yu TC. Economic Burden of COPD in the Presence of Comorbidities. Chest. 2015 Jul;148(1):138-50. doi: 10.1378/chest.14-2434. https://doi.org/10.1378/chest.14-2434

27. Mannino DM, Buist AS. Global burden of COPD: risk factor prevalence, and future trends. Lancet. 2007. Sep; 370:765—773. DOI: 10.1016/S0140-6736(07)61380-4 https://doi.org/10.1016/S0140-6736(07)61380-4

28. Mathers CD, Loncar D. Projections of Global Mortality and Burden of Disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. PMCID: PMC1664601. DOI: 10.1371/journal.pmed.0030442 https://doi.org/10.1371/journal.pmed.0030442

29. Miravitlles M, Price D, Rabe KF. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015 Mar 16;10:549-64. doi: 10.2147/COPD.S71913. https://doi.org/10.2147/COPD.S71913

30. Názara Otero CA, Baloira Villar A. The continuum of COPD and cardiovascular risk: A global scenario of disease. Clin Investig Arterioscler. 2015 May-Jun;27(3):144-7. DOI: 10.1016/j.arteri.2014.09.003 https://doi.org/10.1016/j.arteri.2014.09.003

31. Reda AA, Kotz D, Kocks JW. Reliability and validity of the clinical COPD questionniare and chronic respiratory questionnaire. Respir Med. 2010 Nov;104(11):1675-82. doi: 10.1016/j.rmed.2010.04.023. https://doi.org/10.1016/j.rmed.2010.04.023

32. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000 May;117(5 Suppl 2):398-401. PMID: 10843984

33. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009 Aug 29;374(9691):733-43. doi: 10.1016/S0140-6736(09)61303-9. https://doi.org/10.1016/S0140-6736(09)61303-9

34. Simon PM, Schwartzstein RM, Weiss JW. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 1990 Nov;142(5):1009-14. DOI: 10.1164/ajrccm/142.5.1009 https://doi.org/10.1164/ajrccm/142.5.1009

35. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Sep 24;300(12):1439-50. doi: 10.1001/jama.300.12.1439. https://doi.org/10.1001/jama.300.12.1439

36. Stockley RA, O’Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000 Jun;117(6):1638-45. PMID: 10858396.

37. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005 Jun 25-Jul 1;365(9478):2225-36. Review. PMID: 15978931.

38. Torres-Duque C, Maldonado D, Perez-Padilla R. Biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc. 2008 Jul 15;5(5):577-90. doi: 10.1513/pats.200707-100RP. https://doi.org/10.1513/pats.200707-100RP

39. van der Molen T, Willemse BW, Schokker S. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003 Apr 28;1:13. PMCID: PMC156640

40. Viegi G, Pistelli F, Sherrill DL. Definition, epidemiology and natural history of COPD. Series ”comprehensive management of end-stage COPD” Edited by N. Ambrosino and R. Goldstein Number 1 in this Series. European Respiratory Journal. 2007;30:993-1013. DOI: 10.1183/09031936.00082507 https://doi.org/10.1183/09031936.00082507

41. Zwar NA, Marks GB, Hermiz O. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. Med J Aust. 2011 Aug 15;195(4):168-71. PMID: 21843115

42. Baymakanova GE, Avdeev SN. [A role of biomarkers in chronic obstructive pulmonary disease]. Pul’monologiya. 2013;3:105-110. Russian.

43. Myhajljuk IO, Kyrjuk OH, Artysh IuP. Stan imunnoi’ systemy legeniv v normi i pry hronichnyh nespecyfichnyh zahvorjuvannjah. Galician medical journal 2005;12(4):152-154. Ukrainian.

44. Ovcharenko SI, Leshchenko IV. Sovremennye problemy diagnostiki khronicheskoi obstruktivnoi bolezni legkikh. Ross Med Zh. 2007;10:23—24. Russian.

45. Ovcharenko SI, Galetskayte YaK. Evoliutsiia global’noi initsiativy po khronicheskoi obstrutivnoi bolezni legkikh i novyi podkhod k protivovospalitel’noi terapii. Lechaschiy vrach. 2014;1. URL:http://www.lvrach.ru/2014/01/15435880/ Russian.

46. Todoriko LD. Dyferencijne zastosuvannja bronholitykiv u likuvanni HOZL u osib starshyh vikovyh grup. Klinichna imunologija, alergologija, infektologija. 2011;3:83—86. Ukrainian.

47. Feshhenko JuI, Jashyna LO, Dzjublyk OJa. Hronichne obstruktyvne zahvorjuvannja legen’: etiologija, patogenez, klasyfikacija, diagnostyka, terapija (proekt nacional’noi’ ugody): materialy z’i’zdu. Ukrai’ns’kyj pul’monologichnyj zhurnal. 2013;3:7—12. Ukrainian.